Fast LC-MS/MS analysis of tacrolimus, sirolimus, everolimus and cyclosporin A in dried blood spots and the influence of the hematocrit and immunosuppressant concentration on recovery
We developed a method for the analysis of four immunosuppressants in dried blood spot (DBS) samples to facilitate therapeutic drug monitoring for transplant patients outside the hospital. An 8mm disc from the central part of the DBS was punched, extracted and followed by LC-MS/MS analysis. The metho...
Gespeichert in:
| Veröffentlicht in: | Talanta (Oxford) Jg. 115; S. 47 - 54 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Netherlands
Elsevier B.V
15.10.2013
|
| Schlagworte: | |
| ISSN: | 0039-9140, 1873-3573, 1873-3573 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | We developed a method for the analysis of four immunosuppressants in dried blood spot (DBS) samples to facilitate therapeutic drug monitoring for transplant patients outside the hospital. An 8mm disc from the central part of the DBS was punched, extracted and followed by LC-MS/MS analysis. The method was validated with ranges from 1.00–50.0µg/L for tacrolimus, sirolimus and everolimus, and from 20.0–2000µg/L for cyclosporin A. The validation showed a maximum overall bias of 13.0% for the sirolimus LLOQ, while the maximum overall CV was 15.7% for the everolimus LLOQ. All four immunosuppressants showed to be stable in DBS for at least 7 days at 22°C. The volume of the blood spot showed to have minor effect on measured concentrations. A cross-validation test between the 31 ET CHR paper and the Whatman FTA DMPK-C cards showed no significant difference between the two types of paper. During validation the hematocrit (HT) showed to have significant influence on the analytical results. When the measured concentrations were corrected for the effect of the HT, biases improved significantly. Additional recovery tests proved that the combination of especially low HT and high concentration does not only affect the spot size but can also affect the extraction recoveries of sirolimus and especially everolimus. Although the tested parameters like HT and concentrations are extreme and unlikely for routine analysis of outpatients, the fundamental effect of the combination of these parameters on extraction recoveries are proven with this research. The protein binding in the blood and hydrogen binding to the cellulose of the paper is suggested to influence extractions and gives new insights in the extraction methodology of DBS samples.
The observed HT effect during the validation appeared to be negligible during the correlation study as no concentration corrections for the HT values were needed. Nevertheless, results from DBS samples with extremely high concentrations combined with extremely low HT values should be interpreted with caution. The patient correlation study showed good correlations with R2 values higher than 0.87 between venous whole blood and venous DBS samples were observed for all four immunosuppressants. The Passing & Bablok plots showed positive biases of the slopes of 18% for tacrolimus and less than 12% for sirolimus, everolimus and cyclosporin A. The validated method, proved stability of the immunosuppressants in DBS, and the correlation study showed the capability of the DBS method to be used as an alternative for whole blood analysis in therapeutic drug monitoring.
•Fast dried blood spot analysis without extensive sample preparation.•Cross-validation test performed for 31 ET CHR paper and Whatman FTA DMPK-C cards.•The performed correlation study showed good correlations.•Immunosuppressant extraction was affected by extreme concentration and hematocrit.•Substance protein binding and cellulose binding affinity may affect recovery. |
|---|---|
| AbstractList | We developed a method for the analysis of four immunosuppressants in dried blood spot (DBS) samples to facilitate therapeutic drug monitoring for transplant patients outside the hospital. An 8mm disc from the central part of the DBS was punched, extracted and followed by LC-MS/MS analysis. The method was validated with ranges from 1.00–50.0µg/L for tacrolimus, sirolimus and everolimus, and from 20.0–2000µg/L for cyclosporin A. The validation showed a maximum overall bias of 13.0% for the sirolimus LLOQ, while the maximum overall CV was 15.7% for the everolimus LLOQ. All four immunosuppressants showed to be stable in DBS for at least 7 days at 22°C. The volume of the blood spot showed to have minor effect on measured concentrations. A cross-validation test between the 31 ET CHR paper and the Whatman FTA DMPK-C cards showed no significant difference between the two types of paper. During validation the hematocrit (HT) showed to have significant influence on the analytical results. When the measured concentrations were corrected for the effect of the HT, biases improved significantly. Additional recovery tests proved that the combination of especially low HT and high concentration does not only affect the spot size but can also affect the extraction recoveries of sirolimus and especially everolimus. Although the tested parameters like HT and concentrations are extreme and unlikely for routine analysis of outpatients, the fundamental effect of the combination of these parameters on extraction recoveries are proven with this research. The protein binding in the blood and hydrogen binding to the cellulose of the paper is suggested to influence extractions and gives new insights in the extraction methodology of DBS samples. The observed HT effect during the validation appeared to be negligible during the correlation study as no concentration corrections for the HT values were needed. Nevertheless, results from DBS samples with extremely high concentrations combined with extremely low HT values should be interpreted with caution. The patient correlation study showed good correlations with R² values higher than 0.87 between venous whole blood and venous DBS samples were observed for all four immunosuppressants. The Passing & Bablok plots showed positive biases of the slopes of 18% for tacrolimus and less than 12% for sirolimus, everolimus and cyclosporin A. The validated method, proved stability of the immunosuppressants in DBS, and the correlation study showed the capability of the DBS method to be used as an alternative for whole blood analysis in therapeutic drug monitoring. We developed a method for the analysis of four immunosuppressants in dried blood spot (DBS) samples to facilitate therapeutic drug monitoring for transplant patients outside the hospital. An 8mm disc from the central part of the DBS was punched, extracted and followed by LC-MS/MS analysis. The method was validated with ranges from 1.00-50.0 µg/L for tacrolimus, sirolimus and everolimus, and from 20.0-2000 µg/L for cyclosporin A. The validation showed a maximum overall bias of 13.0% for the sirolimus LLOQ, while the maximum overall CV was 15.7% for the everolimus LLOQ. All four immunosuppressants showed to be stable in DBS for at least 7 days at 22°C. The volume of the blood spot showed to have minor effect on measured concentrations. A cross-validation test between the 31 ET CHR paper and the Whatman FTA DMPK-C cards showed no significant difference between the two types of paper. During validation the hematocrit (HT) showed to have significant influence on the analytical results. When the measured concentrations were corrected for the effect of the HT, biases improved significantly. Additional recovery tests proved that the combination of especially low HT and high concentration does not only affect the spot size but can also affect the extraction recoveries of sirolimus and especially everolimus. Although the tested parameters like HT and concentrations are extreme and unlikely for routine analysis of outpatients, the fundamental effect of the combination of these parameters on extraction recoveries are proven with this research. The protein binding in the blood and hydrogen binding to the cellulose of the paper is suggested to influence extractions and gives new insights in the extraction methodology of DBS samples. The observed HT effect during the validation appeared to be negligible during the correlation study as no concentration corrections for the HT values were needed. Nevertheless, results from DBS samples with extremely high concentrations combined with extremely low HT values should be interpreted with caution. The patient correlation study showed good correlations with R(2) values higher than 0.87 between venous whole blood and venous DBS samples were observed for all four immunosuppressants. The Passing & Bablok plots showed positive biases of the slopes of 18% for tacrolimus and less than 12% for sirolimus, everolimus and cyclosporin A. The validated method, proved stability of the immunosuppressants in DBS, and the correlation study showed the capability of the DBS method to be used as an alternative for whole blood analysis in therapeutic drug monitoring. We developed a method for the analysis of four immunosuppressants in dried blood spot (DBS) samples to facilitate therapeutic drug monitoring for transplant patients outside the hospital. An 8 mm disc from the central part of the DBS was punched, extracted and followed by LC-MS/MS analysis. The method was validated with ranges from 1.00a50.0 Amg/L for tacrolimus, sirolimus and everolimus, and from 20.0a2000 Amg/L for cyclosporin A. The validation showed a maximum overall bias of 13.0% for the sirolimus LLOQ, while the maximum overall CV was 15.7% for the everolimus LLOQ. All four immunosuppressants showed to be stable in DBS for at least 7 days at 22 degree C. The volume of the blood spot showed to have minor effect on measured concentrations. A cross-validation test between the 31 ET CHR paper and the Whatman FTA DMPK-C cards showed no significant difference between the two types of paper. During validation the hematocrit (HT) showed to have significant influence on the analytical results. When the measured concentrations were corrected for the effect of the HT, biases improved significantly. Additional recovery tests proved that the combination of especially low HT and high concentration does not only affect the spot size but can also affect the extraction recoveries of sirolimus and especially everolimus. Although the tested parameters like HT and concentrations are extreme and unlikely for routine analysis of outpatients, the fundamental effect of the combination of these parameters on extraction recoveries are proven with this research. The protein binding in the blood and hydrogen binding to the cellulose of the paper is suggested to influence extractions and gives new insights in the extraction methodology of DBS samples. We developed a method for the analysis of four immunosuppressants in dried blood spot (DBS) samples to facilitate therapeutic drug monitoring for transplant patients outside the hospital. An 8mm disc from the central part of the DBS was punched, extracted and followed by LC-MS/MS analysis. The method was validated with ranges from 1.00–50.0µg/L for tacrolimus, sirolimus and everolimus, and from 20.0–2000µg/L for cyclosporin A. The validation showed a maximum overall bias of 13.0% for the sirolimus LLOQ, while the maximum overall CV was 15.7% for the everolimus LLOQ. All four immunosuppressants showed to be stable in DBS for at least 7 days at 22°C. The volume of the blood spot showed to have minor effect on measured concentrations. A cross-validation test between the 31 ET CHR paper and the Whatman FTA DMPK-C cards showed no significant difference between the two types of paper. During validation the hematocrit (HT) showed to have significant influence on the analytical results. When the measured concentrations were corrected for the effect of the HT, biases improved significantly. Additional recovery tests proved that the combination of especially low HT and high concentration does not only affect the spot size but can also affect the extraction recoveries of sirolimus and especially everolimus. Although the tested parameters like HT and concentrations are extreme and unlikely for routine analysis of outpatients, the fundamental effect of the combination of these parameters on extraction recoveries are proven with this research. The protein binding in the blood and hydrogen binding to the cellulose of the paper is suggested to influence extractions and gives new insights in the extraction methodology of DBS samples. The observed HT effect during the validation appeared to be negligible during the correlation study as no concentration corrections for the HT values were needed. Nevertheless, results from DBS samples with extremely high concentrations combined with extremely low HT values should be interpreted with caution. The patient correlation study showed good correlations with R2 values higher than 0.87 between venous whole blood and venous DBS samples were observed for all four immunosuppressants. The Passing & Bablok plots showed positive biases of the slopes of 18% for tacrolimus and less than 12% for sirolimus, everolimus and cyclosporin A. The validated method, proved stability of the immunosuppressants in DBS, and the correlation study showed the capability of the DBS method to be used as an alternative for whole blood analysis in therapeutic drug monitoring. •Fast dried blood spot analysis without extensive sample preparation.•Cross-validation test performed for 31 ET CHR paper and Whatman FTA DMPK-C cards.•The performed correlation study showed good correlations.•Immunosuppressant extraction was affected by extreme concentration and hematocrit.•Substance protein binding and cellulose binding affinity may affect recovery. We developed a method for the analysis of four immunosuppressants in dried blood spot (DBS) samples to facilitate therapeutic drug monitoring for transplant patients outside the hospital. An 8mm disc from the central part of the DBS was punched, extracted and followed by LC-MS/MS analysis. The method was validated with ranges from 1.00-50.0 µg/L for tacrolimus, sirolimus and everolimus, and from 20.0-2000 µg/L for cyclosporin A. The validation showed a maximum overall bias of 13.0% for the sirolimus LLOQ, while the maximum overall CV was 15.7% for the everolimus LLOQ. All four immunosuppressants showed to be stable in DBS for at least 7 days at 22°C. The volume of the blood spot showed to have minor effect on measured concentrations. A cross-validation test between the 31 ET CHR paper and the Whatman FTA DMPK-C cards showed no significant difference between the two types of paper. During validation the hematocrit (HT) showed to have significant influence on the analytical results. When the measured concentrations were corrected for the effect of the HT, biases improved significantly. Additional recovery tests proved that the combination of especially low HT and high concentration does not only affect the spot size but can also affect the extraction recoveries of sirolimus and especially everolimus. Although the tested parameters like HT and concentrations are extreme and unlikely for routine analysis of outpatients, the fundamental effect of the combination of these parameters on extraction recoveries are proven with this research. The protein binding in the blood and hydrogen binding to the cellulose of the paper is suggested to influence extractions and gives new insights in the extraction methodology of DBS samples. The observed HT effect during the validation appeared to be negligible during the correlation study as no concentration corrections for the HT values were needed. Nevertheless, results from DBS samples with extremely high concentrations combined with extremely low HT values should be interpreted with caution. The patient correlation study showed good correlations with R(2) values higher than 0.87 between venous whole blood and venous DBS samples were observed for all four immunosuppressants. The Passing & Bablok plots showed positive biases of the slopes of 18% for tacrolimus and less than 12% for sirolimus, everolimus and cyclosporin A. The validated method, proved stability of the immunosuppressants in DBS, and the correlation study showed the capability of the DBS method to be used as an alternative for whole blood analysis in therapeutic drug monitoring.We developed a method for the analysis of four immunosuppressants in dried blood spot (DBS) samples to facilitate therapeutic drug monitoring for transplant patients outside the hospital. An 8mm disc from the central part of the DBS was punched, extracted and followed by LC-MS/MS analysis. The method was validated with ranges from 1.00-50.0 µg/L for tacrolimus, sirolimus and everolimus, and from 20.0-2000 µg/L for cyclosporin A. The validation showed a maximum overall bias of 13.0% for the sirolimus LLOQ, while the maximum overall CV was 15.7% for the everolimus LLOQ. All four immunosuppressants showed to be stable in DBS for at least 7 days at 22°C. The volume of the blood spot showed to have minor effect on measured concentrations. A cross-validation test between the 31 ET CHR paper and the Whatman FTA DMPK-C cards showed no significant difference between the two types of paper. During validation the hematocrit (HT) showed to have significant influence on the analytical results. When the measured concentrations were corrected for the effect of the HT, biases improved significantly. Additional recovery tests proved that the combination of especially low HT and high concentration does not only affect the spot size but can also affect the extraction recoveries of sirolimus and especially everolimus. Although the tested parameters like HT and concentrations are extreme and unlikely for routine analysis of outpatients, the fundamental effect of the combination of these parameters on extraction recoveries are proven with this research. The protein binding in the blood and hydrogen binding to the cellulose of the paper is suggested to influence extractions and gives new insights in the extraction methodology of DBS samples. The observed HT effect during the validation appeared to be negligible during the correlation study as no concentration corrections for the HT values were needed. Nevertheless, results from DBS samples with extremely high concentrations combined with extremely low HT values should be interpreted with caution. The patient correlation study showed good correlations with R(2) values higher than 0.87 between venous whole blood and venous DBS samples were observed for all four immunosuppressants. The Passing & Bablok plots showed positive biases of the slopes of 18% for tacrolimus and less than 12% for sirolimus, everolimus and cyclosporin A. The validated method, proved stability of the immunosuppressants in DBS, and the correlation study showed the capability of the DBS method to be used as an alternative for whole blood analysis in therapeutic drug monitoring. |
| Author | Alffenaar, Jan-Willem C. Greijdanus, Ben Koster, Remco A. Uges, Donald R.A. |
| Author_xml | – sequence: 1 givenname: Remco A. surname: Koster fullname: Koster, Remco A. email: r.koster@umcg.nl – sequence: 2 givenname: Jan-Willem C. surname: Alffenaar fullname: Alffenaar, Jan-Willem C. – sequence: 3 givenname: Ben surname: Greijdanus fullname: Greijdanus, Ben – sequence: 4 givenname: Donald R.A. surname: Uges fullname: Uges, Donald R.A. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24054560$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkk1vEzEQhi1URNPCTwB85MCm_ljvhzigKqKAlIpD6Nnyemepo911sL2V8sf4fUyyoQcukSzbGj_jsd93rsjF6Ecg5C1nS854cbNdJtObMZmlYFwuWb5konxBFrwqZSZVKS_IgjFZZzXP2SW5inHLGBOSyVfkUuRM5apgC_LnzsRE16vsfnNzv6FmNP0-ukh9R5OxwfdumOJHGt3zFp7gtEe6pXZvex93PriR3lKc2uCgpU3vfUsxnmYsPQIedv0Eo4Xj7Rh4hMEkb4NLR8YNwzT6OO12AWLEv1HrkR5TMMn5keIIYD3W378mLzvTR3hzWq_Jw92Xn6tv2frH1--r23VmleApKyrVlKbpcltLk4OUpqlabqSqSlHXVhY1swDMVDVwMKouBORSdILnSkDBubwmH-Z7d8H_niAmPbhooUflwU9RC9SUcSXL6izKFVNSCs7ZeTTHFyqOA9F3J3RqBmj1LrjBhL3-5yACagbQrBgDdM8IZ_rQKXqrT52iD52iWa6xUzDv03951qWjzii3689mv5-zO-O1-RVc1A8bBIqDHKLiNRKfZwLQnicHQUfrDua3Dk1MuvXuTI2_YTHoYg |
| CitedBy_id | crossref_primary_10_4155_bio_2021_0247 crossref_primary_10_1515_dx_2018_0034 crossref_primary_10_1111_bcp_16121 crossref_primary_10_1111_bcp_15433 crossref_primary_10_1515_cclm_2019_0053 crossref_primary_10_1515_cclm_2019_1260 crossref_primary_10_1097_FTD_0000000000001281 crossref_primary_10_1093_labmed_lmx056 crossref_primary_10_1111_all_13839 crossref_primary_10_1002_jms_4025 crossref_primary_10_1016_j_jmsacl_2021_01_003 crossref_primary_10_1016_j_microc_2018_12_016 crossref_primary_10_1016_j_jchromb_2024_124154 crossref_primary_10_1097_FTD_0000000000000901 crossref_primary_10_22159_ajpcr_2025v18i7_54759 crossref_primary_10_1007_s00228_016_2036_y crossref_primary_10_1007_s00228_017_2394_0 crossref_primary_10_1002_jcph_558 crossref_primary_10_1007_s40262_014_0177_7 crossref_primary_10_4155_bio_15_12 crossref_primary_10_1016_j_jchromb_2018_04_019 crossref_primary_10_1016_j_chroma_2021_462430 crossref_primary_10_1371_journal_pone_0167433 crossref_primary_10_4155_bio_15_97 crossref_primary_10_4155_bio_15_94 crossref_primary_10_1080_17576180_2025_2477976 crossref_primary_10_1016_j_cca_2014_07_026 crossref_primary_10_1111_bcp_13755 crossref_primary_10_1016_j_ymeth_2025_08_006 crossref_primary_10_1097_FTD_0000000000001066 crossref_primary_10_1097_FTD_0000000000001341 crossref_primary_10_1097_TP_0000000000001591 crossref_primary_10_1016_j_jpba_2021_114315 crossref_primary_10_1080_00032719_2017_1297452 crossref_primary_10_1002_dta_1646 crossref_primary_10_1016_j_jchromb_2023_123721 crossref_primary_10_1002_dta_2290 crossref_primary_10_4155_bio_15_63 crossref_primary_10_1016_j_aca_2023_340797 crossref_primary_10_1097_FTD_0000000000000643 crossref_primary_10_1016_j_clinbiochem_2016_05_001 crossref_primary_10_1097_FTD_0000000000000640 crossref_primary_10_1016_j_cca_2015_12_027 crossref_primary_10_1016_j_clinbiochem_2016_05_004 crossref_primary_10_1016_j_jchromb_2018_11_030 crossref_primary_10_1111_ajt_13935 crossref_primary_10_1002_rcm_9265 crossref_primary_10_4155_bio_2019_0143 crossref_primary_10_1016_j_chroma_2022_463724 crossref_primary_10_1016_j_jpba_2021_114443 crossref_primary_10_1016_j_cca_2022_08_014 crossref_primary_10_1007_s00216_013_7542_5 crossref_primary_10_1007_s10337_025_04421_8 crossref_primary_10_1080_17435390_2017_1292371 crossref_primary_10_1002_elps_201800081 crossref_primary_10_1007_s12272_015_0681_9 crossref_primary_10_1097_FTD_0000000000000834 crossref_primary_10_3390_molecules26020425 crossref_primary_10_1016_j_cjac_2024_100476 crossref_primary_10_1016_j_jpba_2016_06_026 crossref_primary_10_1002_sscp_202400251 crossref_primary_10_1016_j_trac_2016_01_031 crossref_primary_10_1016_j_jpba_2016_01_059 crossref_primary_10_1097_FTD_0000000000000269 crossref_primary_10_1097_FTD_0000000000000422 crossref_primary_10_1016_j_aca_2022_339889 crossref_primary_10_3389_fphar_2023_1126981 crossref_primary_10_4155_bio_2018_0312 crossref_primary_10_1038_s41598_024_63110_y crossref_primary_10_1097_FTD_0000000000000260 crossref_primary_10_1007_s00228_022_03417_9 crossref_primary_10_1016_j_jpba_2018_04_036 crossref_primary_10_1016_j_jpba_2015_02_023 crossref_primary_10_1016_j_clinbiochem_2022_04_014 crossref_primary_10_1177_0004563220937735 crossref_primary_10_3390_diagnostics14171939 crossref_primary_10_1007_s13318_023_00846_4 crossref_primary_10_1016_j_chroma_2023_464086 crossref_primary_10_1093_jalm_jfaa005 crossref_primary_10_1186_s13065_019_0627_2 crossref_primary_10_4155_bio_14_185 crossref_primary_10_1111_bcp_14249 crossref_primary_10_4155_bio_2023_0156 crossref_primary_10_1016_j_jchromb_2016_10_009 crossref_primary_10_1016_j_cca_2024_119864 crossref_primary_10_4155_bio_15_235 crossref_primary_10_1002_jssc_202001267 crossref_primary_10_1007_s10544_019_0412_y crossref_primary_10_1016_j_trac_2015_11_026 crossref_primary_10_1016_j_jchromb_2017_12_012 crossref_primary_10_1002_bmc_5538 crossref_primary_10_1007_s00216_014_8415_2 crossref_primary_10_4155_bio_2016_0296 crossref_primary_10_1097_FTD_0000000000001019 crossref_primary_10_4155_bio_14_298 crossref_primary_10_1016_j_jpba_2017_10_039 crossref_primary_10_4155_bio_15_125 crossref_primary_10_4155_bio_15_35 crossref_primary_10_3389_fphar_2022_925018 crossref_primary_10_1016_j_trac_2015_11_016 crossref_primary_10_1016_j_jpba_2024_116647 crossref_primary_10_3390_pharmaceutics11080394 crossref_primary_10_1016_j_jpba_2018_12_040 crossref_primary_10_1039_C7AN00367F |
| Cites_doi | 10.1016/j.jpba.2008.11.021 10.1016/S0041-1345(98)00587-9 10.1097/FTD.0b013e318192304c 10.1097/01.tp.0000250730.30715.63 10.1016/j.jpba.2006.11.023 10.1056/NEJM199103073241005 10.1016/j.jchromb.2011.03.017 10.1002/bmc.1450 10.1002/bmc.1367 10.1016/j.critrevonc.2005.03.012 10.1016/j.jchromb.2009.03.024 10.1097/FTD.0b013e31819e91ce |
| ContentType | Journal Article |
| Copyright | 2013 Elsevier B.V. 2013 Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2013 Elsevier B.V. – notice: 2013 Elsevier B.V. All rights reserved. |
| DBID | FBQ AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7T5 H94 7S9 L.6 |
| DOI | 10.1016/j.talanta.2013.04.027 |
| DatabaseName | AGRIS CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Immunology Abstracts AIDS and Cancer Research Abstracts AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AIDS and Cancer Research Abstracts Immunology Abstracts AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | AGRICOLA MEDLINE AIDS and Cancer Research Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Chemistry |
| EISSN | 1873-3573 |
| EndPage | 54 |
| ExternalDocumentID | 24054560 10_1016_j_talanta_2013_04_027 US201600012819 S0039914013003317 |
| Genre | Journal Article |
| GroupedDBID | --K --M -DZ -~X .~1 0R~ 123 1B1 1RT 1~. 1~5 4.4 457 4G. 53G 5VS 7-5 71M 8P~ 9JN AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AARLI AAXUO ABJNI ABMAC ABXDB ABYKQ ACDAQ ACGFS ACNCT ACRLP ADBBV ADECG ADEZE ADIYS AEBSH AEKER AENEX AFKWA AFTJW AFZHZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV AJSZI ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AXJTR BKOJK BLXMC CS3 DU5 EBS EFJIC EFLBG EO8 EO9 EP2 EP3 F5P FDB FIRID FLBIZ FNPLU FYGXN G-Q GBLVA IHE J1W K-O KOM M36 M41 MO0 N9A O-L O9- OAUVE OZT P-8 P-9 P2P PC. Q38 RNS ROL RPZ SCC SCH SDF SDG SDP SES SPC SPCBC SSK SSZ T5K TN5 TWZ WH7 XPP YK3 YNT ZMT ~02 ~G- 29Q 3O- AAQXK AAYJJ ABEFU ABFNM ABPIF ABPTK ACNNM ADMUD AJQLL ASPBG AVWKF AZFZN EJD FBQ FEDTE FGOYB G8K HMU HVGLF HZ~ R2- RIG SCB SEW WUQ XFK XOL 9DU AAHBH AATTM AAXKI AAYWO AAYXX ABDPE ABWVN ACLOT ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFJKZ AFPUW AGQPQ AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP CITATION EFKBS ~HD CGR CUY CVF ECM EIF NPM SSH 7X8 7T5 H94 7S9 L.6 |
| ID | FETCH-LOGICAL-c521t-685b7abf4c93a4e33ab8d1a3587299c3690cee0a89e1ea5962e432f21452e6113 |
| ISICitedReferencesCount | 118 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000328095600007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0039-9140 1873-3573 |
| IngestDate | Mon Sep 29 02:08:11 EDT 2025 Sun Nov 09 11:09:17 EST 2025 Sun Sep 28 00:34:03 EDT 2025 Thu Apr 03 06:49:25 EDT 2025 Tue Nov 18 22:35:39 EST 2025 Sat Nov 29 07:25:49 EST 2025 Wed Dec 27 18:47:46 EST 2023 Fri Feb 23 02:35:26 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Cyclosporin A Tacrolimus Sirolimus Everolimus Dried blood spot Hematocrit |
| Language | English |
| License | 2013 Elsevier B.V. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c521t-685b7abf4c93a4e33ab8d1a3587299c3690cee0a89e1ea5962e432f21452e6113 |
| Notes | http://dx.doi.org/10.1016/j.talanta.2013.04.027 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 24054560 |
| PQID | 1435851851 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_2000015378 proquest_miscellaneous_1505332110 proquest_miscellaneous_1435851851 pubmed_primary_24054560 crossref_primary_10_1016_j_talanta_2013_04_027 crossref_citationtrail_10_1016_j_talanta_2013_04_027 fao_agris_US201600012819 elsevier_sciencedirect_doi_10_1016_j_talanta_2013_04_027 |
| PublicationCentury | 2000 |
| PublicationDate | 2013-10-15 |
| PublicationDateYYYYMMDD | 2013-10-15 |
| PublicationDate_xml | – month: 10 year: 2013 text: 2013-10-15 day: 15 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Talanta (Oxford) |
| PublicationTitleAlternate | Talanta |
| PublicationYear | 2013 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Wilhelm, den Burger, Vos, Chahbouni, Sinjewel (bib6) 2009; 877 2013 (accessed 25.03.13. Food and Drug Administration, U.S. Department of Health and Human Services, 2001. U.S. National Library of Medicine 2013 (accessed 18.03.13). Li, Tse (bib3) 2010; 24 Hoogtanders, van der Heijden, Christiaans, van de Plas, van Hooff, Stolk (bib9) 2007; 83 Koster, Dijkers, Uges (bib12) 2009; 31 Sedrani, Cottens, Kallen, Schuler (bib15) 1998; 30 Rao, Maurya, Ramesh, Srinivas, Agwane (bib8) 2010; 24 Edelbroek, van der Heijden, Stolk (bib2) 2009; 31 Hoogtanders, van der Heijden, Christiaans, Edelbroek, van Hooff, Stolk (bib10) 2007; 44 Ferrara, Deeg (bib1) 1991; 324 denBurger, Wilhelm, Chahbouni, Vos, Sinjewel, Swart (bib5) 2012; 404 Hinchliffe, Adaway, Keevil, Chromatogr (bib11) 2011; 883–884 National Center for Biotechnology Information, PubChem Compound Database; CID=6473866; CID=5284616; CID=6442177; CID=5284373 Vu, Koster, Alffenaar, Brouwers, Uges (bib4) 2011; 879 van der Heijden, de Beer, Hoogtanders, Christiaans, de Jong, Neef, Stolk (bib7) 2009; 50 Taylor, Watson, Bradley (bib16) 2005; 56 van der Heijden (10.1016/j.talanta.2013.04.027_bib7) 2009; 50 Hinchliffe (10.1016/j.talanta.2013.04.027_bib11) 2011; 883–884 Koster (10.1016/j.talanta.2013.04.027_bib12) 2009; 31 Sedrani (10.1016/j.talanta.2013.04.027_bib15) 1998; 30 Ferrara (10.1016/j.talanta.2013.04.027_bib1) 1991; 324 Rao (10.1016/j.talanta.2013.04.027_bib8) 2010; 24 Hoogtanders (10.1016/j.talanta.2013.04.027_bib10) 2007; 44 Taylor (10.1016/j.talanta.2013.04.027_bib16) 2005; 56 Wilhelm (10.1016/j.talanta.2013.04.027_bib6) 2009; 877 10.1016/j.talanta.2013.04.027_bib13 10.1016/j.talanta.2013.04.027_bib14 denBurger (10.1016/j.talanta.2013.04.027_bib5) 2012; 404 10.1016/j.talanta.2013.04.027_bib17 Vu (10.1016/j.talanta.2013.04.027_bib4) 2011; 879 Li (10.1016/j.talanta.2013.04.027_bib3) 2010; 24 Edelbroek (10.1016/j.talanta.2013.04.027_bib2) 2009; 31 Hoogtanders (10.1016/j.talanta.2013.04.027_bib9) 2007; 83 |
| References_xml | – volume: 44 start-page: 658 year: 2007 end-page: 664 ident: bib10 publication-title: J. Pharm. Biomed. Anal. – reference: , 2013 (accessed 25.03.13. – volume: 879 start-page: 1063 year: 2011 end-page: 1070 ident: bib4 publication-title: J. Chromatogr. B Anal. Technol. Biomed. Life Sci. – volume: 30 start-page: 2192 year: 1998 end-page: 2194 ident: bib15 publication-title: Transplant. Proc. – volume: 56 start-page: 23 year: 2005 end-page: 46 ident: bib16 publication-title: Crit. Rev. Oncol. Hematol. – reference: , 2013 (accessed 18.03.13). – volume: 404 start-page: 6 year: 2012 end-page: 7 ident: bib5 publication-title: AnalAnal.. Bioanal. Bioanal Chem. – reference: Food and Drug Administration, U.S. Department of Health and Human Services, 2001. – volume: 31 start-page: 116 year: 2009 end-page: 125 ident: bib12 publication-title: Ther. Drug Monit. – reference: U.S. National Library of Medicine, – volume: 324 start-page: 667 year: 1991 end-page: 674 ident: bib1 publication-title: N. Engl. J. Med. – volume: 31 start-page: 327 year: 2009 end-page: 336 ident: bib2 publication-title: Ther. Drug Monit. – volume: 83 start-page: 237 year: 2007 end-page: 238 ident: bib9 publication-title: Transplantation – volume: 883–884 start-page: 102 year: 2011 end-page: 107 ident: bib11 publication-title: B Anal. B. Analyt Technol. Biomed. LifeLife. Sci. – volume: 877 start-page: 1595 year: 2009 end-page: 1598 ident: bib6 publication-title: J. Chromatogr. B Anal. Technol. Biomed. Life Sci. – reference: National Center for Biotechnology Information, PubChem Compound Database; CID=6473866; CID=5284616; CID=6442177; CID=5284373; – volume: 24 start-page: 1356 year: 2010 end-page: 1364 ident: bib8 publication-title: Biomed. Chromatogr. – volume: 50 start-page: 664 year: 2009 end-page: 670 ident: bib7 publication-title: J. Pharm. Biomed. Anal. – volume: 24 start-page: 49 year: 2010 end-page: 65 ident: bib3 publication-title: Biomed. Chromatogr. – volume: 50 start-page: 664 year: 2009 ident: 10.1016/j.talanta.2013.04.027_bib7 publication-title: J. Pharm. Biomed. Anal. doi: 10.1016/j.jpba.2008.11.021 – volume: 883–884 start-page: 102 year: 2011 ident: 10.1016/j.talanta.2013.04.027_bib11 publication-title: B Anal. B. Analyt Technol. Biomed. LifeLife. Sci. – ident: 10.1016/j.talanta.2013.04.027_bib13 – ident: 10.1016/j.talanta.2013.04.027_bib14 – volume: 30 start-page: 2192 year: 1998 ident: 10.1016/j.talanta.2013.04.027_bib15 publication-title: Transplant. Proc. doi: 10.1016/S0041-1345(98)00587-9 – volume: 31 start-page: 116 year: 2009 ident: 10.1016/j.talanta.2013.04.027_bib12 publication-title: Ther. Drug Monit. doi: 10.1097/FTD.0b013e318192304c – volume: 83 start-page: 237 year: 2007 ident: 10.1016/j.talanta.2013.04.027_bib9 publication-title: Transplantation doi: 10.1097/01.tp.0000250730.30715.63 – volume: 44 start-page: 658 year: 2007 ident: 10.1016/j.talanta.2013.04.027_bib10 publication-title: J. Pharm. Biomed. Anal. doi: 10.1016/j.jpba.2006.11.023 – volume: 324 start-page: 667 year: 1991 ident: 10.1016/j.talanta.2013.04.027_bib1 publication-title: N. Engl. J. Med. doi: 10.1056/NEJM199103073241005 – volume: 879 start-page: 1063 year: 2011 ident: 10.1016/j.talanta.2013.04.027_bib4 publication-title: J. Chromatogr. B Anal. Technol. Biomed. Life Sci. doi: 10.1016/j.jchromb.2011.03.017 – ident: 10.1016/j.talanta.2013.04.027_bib17 – volume: 24 start-page: 1356 year: 2010 ident: 10.1016/j.talanta.2013.04.027_bib8 publication-title: Biomed. Chromatogr. doi: 10.1002/bmc.1450 – volume: 24 start-page: 49 year: 2010 ident: 10.1016/j.talanta.2013.04.027_bib3 publication-title: Biomed. Chromatogr. doi: 10.1002/bmc.1367 – volume: 404 start-page: 6 year: 2012 ident: 10.1016/j.talanta.2013.04.027_bib5 publication-title: AnalAnal.. Bioanal. Bioanal Chem. – volume: 56 start-page: 23 year: 2005 ident: 10.1016/j.talanta.2013.04.027_bib16 publication-title: Crit. Rev. Oncol. Hematol. doi: 10.1016/j.critrevonc.2005.03.012 – volume: 877 start-page: 1595 year: 2009 ident: 10.1016/j.talanta.2013.04.027_bib6 publication-title: J. Chromatogr. B Anal. Technol. Biomed. Life Sci. doi: 10.1016/j.jchromb.2009.03.024 – volume: 31 start-page: 327 year: 2009 ident: 10.1016/j.talanta.2013.04.027_bib2 publication-title: Ther. Drug Monit. doi: 10.1097/FTD.0b013e31819e91ce |
| SSID | ssj0002303 |
| Score | 2.4437027 |
| Snippet | We developed a method for the analysis of four immunosuppressants in dried blood spot (DBS) samples to facilitate therapeutic drug monitoring for transplant... |
| SourceID | proquest pubmed crossref fao elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 47 |
| SubjectTerms | blood blood volume cellulose Chromatography, Liquid Cyclosporin A cyclosporine Cyclosporine - blood Dried blood spot Dried Blood Spot Testing Drug Monitoring Drug Stability Everolimus Hematocrit hospitals Humans hydrogen Immunosuppressive Agents - blood monitoring patients protein binding rapamycin Sirolimus Sirolimus - analogs & derivatives Sirolimus - blood Solid Phase Microextraction Tacrolimus Tacrolimus - blood Tandem Mass Spectrometry therapeutics |
| Title | Fast LC-MS/MS analysis of tacrolimus, sirolimus, everolimus and cyclosporin A in dried blood spots and the influence of the hematocrit and immunosuppressant concentration on recovery |
| URI | https://dx.doi.org/10.1016/j.talanta.2013.04.027 https://www.ncbi.nlm.nih.gov/pubmed/24054560 https://www.proquest.com/docview/1435851851 https://www.proquest.com/docview/1505332110 https://www.proquest.com/docview/2000015378 |
| Volume | 115 |
| WOSCitedRecordID | wos000328095600007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1873-3573 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002303 issn: 0039-9140 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9owELegnbS9TPts2UflSXujoUmcEOeRoXZb1VZTAYm3yCROBYIEQajYP7Z_ba-7s_MBYqzbw6QoIpZjEu6HfXf-3R0hH00_9GRkjgxfutJwhB0ZsChIw4wsxp3QEmasAoWvvJsbPhz632q1n0UszP3USxK-Xvvz_ypqaANhY-jsP4i7HBQa4DMIHc4gdjj_leAvxDJrXnWN6x6MAWa62Eg7kokQq_TMVkp6y_HGhYQX1Vc61O17OE3R5EV_iKLMLpSyijz3JrRny5J7OS7qnBR8A5UHNoXpSLPXxxiCki5Xc11vJcmQ6q5JoVpdxYiaEKmkW1vMfSRdZkLlQ11rCn5FDE-LgiK3chamlUO2M41jmQjNGr8UieIDy1nlC_68kONJJBL90p-qQLjBncwtCnSWN29bnU2HiKWodTokVHvpdiJ19MzPfJjYdWqoltSTPfeYwVxdSqVcDfKh9Hyus4HmmoHOdr2z5mj3xwQzVuLPgnRBptLn2l61yJbUx0HPxqR--RZmnRzanuvDdHzY-Xo-vCyVCLAM83zR-rGr4LOz337TPrWqHot0v_GklKj-M_I0t35oR6P2OanJ5AV53C2KDr4kPxC9VKH37LpHC-zSNKYVdk9pidxTWuEWekd0A7e0Q-GkcEsVbqnCreoGMKUlbtXo0FDhVvXZwS3dwi2Fo8DtKzK4OO93vxh5aREjxAoeRpu7I0-MYif0mXAkY2LEI0swl4Ox6Yes7ZugPZqC-9KSAitUSYfZMab1t2XbsthrcpCkiTwm1AGDp81FW4Z85HiR9EdRWwoWmYD3mEd-gziFZIIwz7uP5V-mQUGwnAS5QAMUaGA6AQi0QVrlbXOdeOahG3gh9iDXnrVWHABQH7r1GGASiDvQK4JtgDbIhwI7AUABdxNFItPVMkBDC8w1OP7Qx8VQf_Qx7e9jqw1Gl3m8QY40OMsXBnMDLTzzzf4HfEueVJPAO3KQLVbyPXkU3mfj5eKE1L0hP8n_XL8A8a4bKg |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Fast+LC-MS%2FMS+analysis+of+tacrolimus%2C+sirolimus%2C+everolimus+and+cyclosporin+A+in+dried+blood+spots+and+the+influence+of+the+hematocrit+and+immunosuppressant+concentration+on+recovery&rft.jtitle=Talanta+%28Oxford%29&rft.au=Koster%2C+Remco+A&rft.au=Alffenaar%2C+Jan-Willem+C&rft.au=Greijdanus%2C+Ben&rft.au=Uges%2C+Donald+R.A&rft.date=2013-10-15&rft.pub=Elsevier+B.V&rft.issn=0039-9140&rft.eissn=1873-3573&rft.volume=115&rft.spage=47&rft.epage=54&rft_id=info:doi/10.1016%2Fj.talanta.2013.04.027&rft.externalDocID=US201600012819 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0039-9140&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0039-9140&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0039-9140&client=summon |